NASDAQ NMS - GLOBAL MARKET · BEAM
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Beam Therapeutics Inc

Beam Therapeutics Inc

Biotechnology
$29.76
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Earnings absence reason unknown
BEAM
Beam Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BEAM moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BEAM catalysts
About Beam Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
540
Country
US

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$29.76
Last session
Day high
$29.76
Last session
Day low
$29.76
Last session
Previous close
$29.76
52W high
$37.92
-21.52% from high
52W low
$16.31
62% of range
Market cap
$3.1B
EPS
$-4.1900
Beta
2.09
Shares out
103.3M
Avg volume
1.9M
VWAP
$29.76
Last session
Price history computed in-house
1W
+9.82%
1M
+18.57%
3M
-0.10%
1Y
+78.85%
YTD
+7.36%
SMA 50 $29.90 · below
SMA 200 $28.16 · above
52W position 62%

BEAM overview

Veridion Score
59
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BEAM.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BEAM Form 4 filings
Public disclosures

Congress activity in BEAM

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for BEAM in the cached public ledger.

Federal contracts

BEAM contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BEAM in this window.
Lobbying spend

BEAM lobbying filings, year to date.

Registered lobbying filings matched to Beam Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BEAM in this window.
Loading news for BEAM
Analyst ratings
Sovereign unlock shows live analyst consensus for BEAM.
Options
Sovereign unlock shows live options positioning for BEAM.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.